News

Bihar: Complaint filed against Ramdev over Covid-19 medicine claim

PTI Muzaffarpur | Updated on June 24, 2020 Published on June 24, 2020

A criminal complaint has been filed in a Bihar court against yoga guru Ramdev and Patanjali Ayurved MD Acharya Balkrishna, alleging that they have misled and put at risk the lives of lakhs of people by claiming to have developed a medicine to treat Covid-19.

The complaint seeking registration of an FIR on cheating, criminal conspiracy and other charges was filed in the court of Chief Judicial Magistrate Mukesh Kumar here on Tuesday by Tamanna Hashmi, who identifies himself as a social worker and is often in news for his numerous court complaints against politicians over various issues.

The court posted the matter for hearing on June 30.

The complainant has named Ramdev, the convenor of the Patanjali Research Institute, and his aide Balkrishna, the organisation’s chairman, as accused.

The complaint

Hashmi submitted that Ramdev and Balkrishna claimed to have prepared “Coronil tablet” to cure Covid-19, which is nothing but misleading. The complainant submitted that the AYUSH Ministry has asked Patanjali Ayurved to stop advertising and publicising its claims about the medicine.

The AYUSH Ministry has said that they have not been provided any information with regard to the details of the composition of the ayurvedic medicine, Hashmi said.

The complainant has sought registration of a case under IPC sections 420 (cheating and dishonesty inducing delivery of property), 120B (criminal conspiracy) and 270 (malignant act likely to spread infection of disease dangerous to life), among others.

Patanjali’s claim

Ramdev’s herbal medicine company Patanjali Ayurved has launched ‘Coronil tablet and Swasari vati’ medicines claiming they can cure the disease within seven days.

 

It has also claimed that the two Ayurveda-based medicines have shown 100 per cent favourable results during clinical trials on Covid-19 infected patients except those on a life support system. However, the AYUSH Ministry said that the facts of the claim and details of the stated scientific study are not known to it.

It has sought from the company a detailed report on composition, testing and other data of the drugs.

The Ministry also used powers under a 1954 law to ask the firm to “stop advertising/publicizing” claims of corona cure drug until the issue is examined by it. A government notification bars companies from advertising a cure without government approval. But it wasn’t immediately clear if the drug can still be sold.

Ramdev said the medicines have been developed by Patanjali Research Center, Haridwar, and privately-owned National Institute of Medical Science, Jaipur following all protocols with clinically controlled trial-based evidence.

Patanjali group has an estimated turnover of around Rs 10,500 crore.

Published on June 24, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
Maharashtra government against allowing ICSE to conduct board exams in July